Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Fuji
Harvard Business School
US Department of Justice
Colorcon
Covington
Chubb
Chinese Patent Office
Johnson and Johnson

Generated: May 25, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 017555

« Back to Dashboard

NDA 017555 describes SINEMET, which is a drug marketed by Merck Sharp Dohme and is included in two NDAs. It is available from one supplier. Additional details are available on the SINEMET profile page.

The generic ingredient in SINEMET is carbidopa; levodopa. There are eighteen drug master file entries for this compound. Twenty-nine suppliers are listed for this compound. Additional details are available on the carbidopa; levodopa profile page.
Summary for 017555
Tradename:SINEMET
Applicant:Merck Sharp Dohme
Ingredient:carbidopa; levodopa
Patents:0
Therapeutic Class:Antiparkinson Agents
Formulation / Manufacturing:see details
Pharmacology for NDA: 017555
Ingredient-typeAmino Acids, Aromatic
Suppliers and Packaging for NDA: 017555
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
SINEMET carbidopa; levodopa TABLET;ORAL 017555 NDA Merck Sharp & Dohme Corp. 0006-3915 N 0006-3915-68
SINEMET carbidopa; levodopa TABLET;ORAL 017555 NDA Merck Sharp & Dohme Corp. 0006-3916 N 0006-3916-68

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength10MG;100MG
Approval Date:Approved Prior to Jan 1, 1982TE:ABRLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength25MG;250MG
Approval Date:Approved Prior to Jan 1, 1982TE:ABRLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength25MG;100MG
Approval Date:Approved Prior to Jan 1, 1982TE:ABRLD:Yes

Expired US Patents for NDA 017555

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck Sharp Dohme SINEMET carbidopa; levodopa TABLET;ORAL 017555-003 Approved Prior to Jan 1, 1982 ➤ Try a Free Trial ➤ Try a Free Trial
Merck Sharp Dohme SINEMET carbidopa; levodopa TABLET;ORAL 017555-001 Approved Prior to Jan 1, 1982 ➤ Try a Free Trial ➤ Try a Free Trial
Merck Sharp Dohme SINEMET carbidopa; levodopa TABLET;ORAL 017555-001 Approved Prior to Jan 1, 1982 ➤ Try a Free Trial ➤ Try a Free Trial
Merck Sharp Dohme SINEMET carbidopa; levodopa TABLET;ORAL 017555-002 Approved Prior to Jan 1, 1982 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Cantor Fitzgerald
Citi
Accenture
Farmers Insurance
Chinese Patent Office
Moodys
Fish and Richardson
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.